Induction of new TKD mutations occurs as a common secondary intrinsic mechanism of resistance to type II FLT3 inhibitors, for example, in relapsed AML patients with FLT3-ITD mutations received quizartinib or sorafenib therapy [73,76]. This evidence concerns the gene FLT3 and acute myeloid leukemia.